MedImmune expands partnership with USM

Gaithersburg-based MedImmune is expanding its recently announced research partnership with the University of Maryland, Baltimore to include two more UM campuses: College Park and Baltimore County.

MedImmune (the global biologics R&D arm of AstraZeneca) announced the five-year, $6 million collaboration with UMB in September 2013. The goal is to promote and advance the state’s capabilities in bioscience research.

On Tuesday, the company announced that the two other schools would be equally involved. MedImmune also identified the first five joint research projects that will be launched with the University System of Maryland.